VitalDose® EVA excipients - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Participate in the VitalDose excipient discussion. Ken Anderson of Celanese shares insights into EVA excipients technology and invites you to ask questions about one of the most versatile polymers utilized in the pharmaceutical industry.

Are you in search of routes of administration that can breathe new life into your expiring drug patents? Want to learn more about excipients technology for use in novel controlled released products? Find answers to these questions and more at the recently launched blog – VitalDose.com/blog – where Celanese EVA Performance Polymers technical leader, Ken Anderson, Ph.D. will provide regular updates and summaries on the latest research pertaining to EVA excipients.

In participating in the new VitalDose blog, you will learn:

  • The latest news in VitalDose ethylene vinyl acetate (EVA) excipients
  • Technical data on this technology and its applications
  • Solutions to formulation challenges.

EVA polymers have been used for many years in a variety of pharmaceutical and medical device products.

Tailor the dosing and delivery of your API

  • Formulation design versatility
  • Customizable delivery and release profiles
  • Manufacturing process versatility
  • Multiple routes of administration

Learn more about EVA polymers at the VitalDose.com website or e-mail us at VitalDose@Celanese.com.

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FindPharma Custom Search

Click here